N-acetylgalactosamine


Also found in: Wikipedia.

N- acetylgalactosamine

/N- ac·e·tyl·ga·lac·to·sa·mine/ (as″ĕ-til-) (as″ĕ-tēl-gal″ak-tōs´ah-mēn) the acetyl derivative of galactosamine; it is a component of structural glycosaminoglycans, glycolipids, and membrane glycoproteins.

N-acetylgalactosamine

one of the repeating disaccharide units in glycosaminoglycans.
References in periodicals archive ?
The enzyme hydrolyzes the sulfate ester bond ofgalactose 6-sulfate in keratan sulfate and of N-acetylgalactosamine 6-sulfate in chondroitin C.
Nasdaq: BMRN) announced today the initiation of a Phase 1/2 clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome.
National Institute of Advanced Industrial Science and Technology (Tokyo, Japan) has patented an enzyme which transfers N-acetylgalactosamine to N-acetylglucosamine via a .
MPS VI (also known as Maroteaux-Lamy syndrome) is a debilitating, life-threatening genetic disease caused by a deficiency of the enzyme N-acetylgalactosamine 4-sulfatase.
Viral particles bind specifically to digestive ducts (midgut, main and secondary ducts, and tubules) by carbohydrate structures with a terminal N-acetylgalactosamine residue in an [alpha] linkage (same binding site used for recognition of human histo-blood group antigens).
has begun dosing patients in a Phase 2 clinical trial of Aryplase (recombinant human N-acetylgalactosamine 4-sulfatase or arylsulfatase B), an investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI).
Out of the million or so structures on each A cell, about 50,000 have a second copy of the final three-sugar sequence, which includes an N-acetylgalactosamine.
Further, iLNPs were engineered with the carbohydrate N-acetylgalactosamine (GalNAc) to achieve targeting to the asialoglycoprotein receptor (ASGPR) as an alternative targeting strategy for the hepatic delivery of RNAi therapeutics.
The purified compounds from a patient with [alpha]-NAGA deficiency (4), kindly provided by Dr Hirabayashi (Riken, Tsukuba, Japan), were NeuAc[alpha]2-3Gal[beta]1-3[NeuAc[alpha]26]Ga1NAc[alpha]1-Ser/Thr, where NeuAc is acetylneuraminic acid and Ga1NAc is N-acetylgalactosamine.
has announced that BioMarin has completed the 24 week treatment stage of its Phase I clinical trial of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB), an enzyme replacement therapy for the treatment of MPS-VI.
Nasdaq:BMRN) and (Swiss SWX New Market:BMRN), today announced that BioMarin began dosing patients last month in a Phase 2 clinical trial of Aryplase(TM) (recombinant human N-acetylgalactosamine 4-sulfatase or arylsulfatase B), an investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI).
Nasdaq and SWX New Market: BMRN), today announced that recombinant human N-acetylgalactosamine 4-sulfatase (rhASB), an investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) VI, was well tolerated at both dose levels by the six patients evaluated in the Company's Phase I clinical trial, and there were no drug-related serious adverse events during the study.

Full browser ?